DK1581535T3 - Pyrrolopyridazinderivater - Google Patents

Pyrrolopyridazinderivater

Info

Publication number
DK1581535T3
DK1581535T3 DK03789642T DK03789642T DK1581535T3 DK 1581535 T3 DK1581535 T3 DK 1581535T3 DK 03789642 T DK03789642 T DK 03789642T DK 03789642 T DK03789642 T DK 03789642T DK 1581535 T3 DK1581535 T3 DK 1581535T3
Authority
DK
Denmark
Prior art keywords
pyrrolopyridazine
Prior art date
Application number
DK03789642T
Other languages
English (en)
Other versions
DK1581535T5 (da
Inventor
Yoshito Abe
Makoto Inoue
T Mizutani
Kozo Sawada
Kazuhiko Ohne
M Okumura
Yuki Sawada
K Imamura
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003900189A external-priority patent/AU2003900189A0/en
Priority claimed from AU2003903628A external-priority patent/AU2003903628A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK1581535T3 publication Critical patent/DK1581535T3/da
Publication of DK1581535T5 publication Critical patent/DK1581535T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03789642T 2003-01-09 2003-12-26 Pyrrolopyridazinderivater DK1581535T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003900189A AU2003900189A0 (en) 2003-01-09 2003-01-09 Heterocyclic derivatives
AU2003903628A AU2003903628A0 (en) 2003-07-14 2003-07-14 Pyrrolopyridazine derivatives
PCT/JP2003/017091 WO2004063197A1 (en) 2003-01-09 2003-12-26 Pyrrolopyridazine derivatives

Publications (2)

Publication Number Publication Date
DK1581535T3 true DK1581535T3 (da) 2008-02-11
DK1581535T5 DK1581535T5 (da) 2009-12-21

Family

ID=32714072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03789642T DK1581535T5 (da) 2003-01-09 2003-12-26 Pyrrolopyridazinderivater

Country Status (22)

Country Link
US (2) US7153854B2 (da)
EP (1) EP1581535B3 (da)
JP (1) JP4671104B2 (da)
KR (1) KR101026819B1 (da)
AR (1) AR042833A1 (da)
AT (1) ATE376549T1 (da)
BR (1) BR0317358A (da)
CA (1) CA2513081C (da)
CY (1) CY1107084T1 (da)
DE (1) DE60317102T3 (da)
DK (1) DK1581535T5 (da)
ES (1) ES2291729T7 (da)
HK (1) HK1088900A1 (da)
IL (1) IL169500A0 (da)
MX (1) MXPA05007462A (da)
NO (1) NO20053748L (da)
NZ (1) NZ541232A (da)
PL (1) PL378245A1 (da)
PT (1) PT1581535E (da)
RU (1) RU2328499C2 (da)
TW (1) TWI332004B (da)
WO (1) WO2004063197A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541232A (en) 2003-01-09 2008-02-29 Astellas Pharma Inc Pyrrolopyridazine derivatives
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
DE602005011286D1 (en) * 2004-07-05 2009-01-08 Astellas Pharma Inc Pyrazolopyridinderivate
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
JP2009114123A (ja) * 2007-11-06 2009-05-28 Astellas Pharma Inc ２−アシル−１−アミノピロール化合物の新規製造法
EP2674417A3 (en) * 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
ES2865026T3 (es) * 2010-04-23 2021-10-14 Steam Tech Llc Sistema de limpiaparabrisas de superficie
KR20130083389A (ko) * 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
WO2012033144A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 ピラゾロキノリン化合物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
JP5988941B2 (ja) * 2012-09-20 2016-09-07 富士フイルム株式会社 有機銅錯体、有機銅錯体溶液、銅酸化物薄膜、銅酸化物薄膜の製造方法、および、化合物
US10434132B2 (en) * 2013-06-04 2019-10-08 Academia Sinica Galactolipids-enriched plant extracts and the uses thereof
US11066412B2 (en) * 2017-11-17 2021-07-20 Academia Sinica Substituted pyrrolo[2,1-a]phthalazines and benzo[g]pyrrolo[2,1-a]phthalazines for the treatment of cancer
KR102607510B1 (ko) * 2018-10-17 2023-11-30 수벤 라이프 사이언시스 리미티드 무스카린 m1 수용체 양성 알로스테릭 조절제로서의 피롤로-피리다진 유도체
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
KR20230028268A (ko) 2020-05-29 2023-02-28 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 헤테로시클릭 화합물
AU2022377394A1 (en) 2021-11-01 2024-06-13 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7891891A (en) * 1990-05-25 1991-12-31 Fujisawa Pharmaceutical Co., Ltd. Pyrrolopyridazine compounds
CA2332528A1 (en) * 1998-05-21 1999-11-25 Shionogi & Co., Ltd. Pyrrolo[1,2-b]pyridazine spla2 inhibitory
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
PL366376A1 (en) * 2000-11-17 2005-01-24 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US20040254189A1 (en) * 2001-08-23 2004-12-16 Hideaki Nagaya Jnk inhibitors
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
NZ541232A (en) 2003-01-09 2008-02-29 Astellas Pharma Inc Pyrrolopyridazine derivatives

Also Published As

Publication number Publication date
KR20050092738A (ko) 2005-09-22
AR042833A1 (es) 2005-07-06
JP2006515597A (ja) 2006-06-01
DE60317102D1 (de) 2007-12-06
RU2328499C2 (ru) 2008-07-10
CA2513081C (en) 2011-04-19
EP1581535B3 (en) 2009-09-02
DE60317102T2 (de) 2009-01-29
DK1581535T5 (da) 2009-12-21
ATE376549T1 (de) 2007-11-15
PL378245A1 (pl) 2006-03-20
BR0317358A (pt) 2005-12-13
ES2291729T3 (es) 2008-03-01
NZ541232A (en) 2008-02-29
HK1088900A1 (en) 2006-11-17
EP1581535B1 (en) 2007-10-24
US7153854B2 (en) 2006-12-26
US20050075342A1 (en) 2005-04-07
WO2004063197A1 (en) 2004-07-29
TW200418861A (en) 2004-10-01
CA2513081A1 (en) 2004-07-29
DE60317102T3 (de) 2010-02-18
RU2005125209A (ru) 2006-01-27
EP1581535B9 (en) 2008-03-19
MXPA05007462A (es) 2006-01-27
PT1581535E (pt) 2007-12-12
NO20053748L (no) 2005-10-07
US7317009B2 (en) 2008-01-08
TWI332004B (en) 2010-10-21
EP1581535A1 (en) 2005-10-05
KR101026819B1 (ko) 2011-04-04
US20060270678A1 (en) 2006-11-30
IL169500A0 (en) 2007-07-04
ES2291729T7 (es) 2010-03-31
CY1107084T1 (el) 2012-10-24
JP4671104B2 (ja) 2011-04-13
NO20053748D0 (no) 2005-08-04

Similar Documents

Publication Publication Date Title
DK1581535T5 (da) Pyrrolopyridazinderivater
ATE363383T1 (de) Schlingenware
DE502004001683D1 (de) Kabelführung
SE0302091L (sv) Genomföring
AT502792A5 (de) Düsenanpressvorrichtung
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
DE502004007911D1 (de) Wischblatt
DE112004000620D2 (de) Struktoguss
DE502004000672D1 (de) Pigmentpreparationen
DE502004001524D1 (de) Hydrolager
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DE502004001629D1 (de) Bremsenprüfstand
DE502004003122D1 (de) Hydrolager
DE502004002978D1 (de) N-biarylamide
DE502004000518D1 (de) Mitgängergabelhubwagen
DE502004006563D1 (de) Brieftaubenkonstatiersystem
DE10394329D2 (de) Mäanderstent
DE502004005162D1 (de) Leistungsregelvorricthung
DE10355350A8 (de) Elektromodul
ATE406350T1 (de) Prolinylarylacetamide
DE112004002227D2 (de) Nietverarbeitungsgerät
DE10329218B4 (de) Hotflue
DE502004007251D1 (de) En 2-arylpropenalen
DE112004001561D2 (de) Getriebene-Antreibseinheit